Ekso Bionics Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2018

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth the computation of basic and diluted net loss per share:

	Three months ended March 31,
	2018		2017
Numerator:
Net loss
Basic	$	(7,901)	$	(8,302)
Adjustment for revaluation of warrant liability		-		-
Diluted	$	(7,901)	$	(8,302)

Denominator:
Weighted-average number of shares, basic		60,146		21,899
Effect of dilutive warrants		-		-
Weighted-average numbers of shares, diluted		60,146		21,899

Net loss per share, basic	$	(0.13)	$	(0.38)
Net loss per share, diluted	$	(0.13)	$	(0.38)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following table sets forth potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:

	Three months ended March 31,
	2018		2017
Options to purchase common stock		2,898		2,466
Restricted stock		125		-
Warrants for common stock		3,396		3,226
Total common stock equivalents		6,419		5,692